Gilead Sciences (GILD) Invested Capital (2009 - 2026)

Gilead Sciences (GILD) has reported Invested Capital for 18 consecutive years, with $40.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Invested Capital fell 14.48% year-over-year to $40.5 billion; the trailing twelve-month figure through Jun 2026 stood at $40.5 billion (down 14.48% YoY), and the FY2025 full-year result was $50.4 billion, up 5.6% from the prior year.
• Invested Capital slipped to $40.5 billion in Q2 2026 per GILD's latest filing, from $46.9 billion in the prior quarter.
• Across five years, Invested Capital topped out at $50.4 billion in Q4 2025 and bottomed at $40.5 billion in Q2 2026.
• Historically, Invested Capital has averaged $47.3 billion across 5 years, with a median of $47.6 billion in 2022.
• The sharpest annual moves came in 2025 and 2026: Invested Capital increased 13.43% in 2025, then decreased 14.48% in 2026.
• Over 5 years, Invested Capital stood at $48.7 billion in 2022, then increased by 1.69% to $49.5 billion in 2023, then retreated by 3.56% to $47.8 billion in 2024, then rose by 5.6% to $50.4 billion in 2025, then decreased by 19.74% to $40.5 billion in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $40.5 billion, $46.9 billion, and $50.4 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.